US Patent:
20200061095, Feb 27, 2020
Inventors:
- Norcross GA, US
Eliezer Zomer - Newton MA, US
Deirdre Slate - Berlin MA, US
Joseph M. Johnson - Arlington MA, US
Ryan George - Framingham MA, US
Sharon Shechter - Andover MA, US
Raphael Nir - Needham MA, US
International Classification:
A61K 31/7056
A61K 31/4439
A61P 3/10
A61K 45/06
Abstract:
Aspects of the invention relate to novel synthetic compounds for treatment of metabolic diseases partially associated with systemic insulin resistance caused by Galectin proteins binding and inhibiting insulin and TGFb1 receptors causing physiological disturbances in the insulin pathways.